Years of chronic reflux can lead to Barrett’s esophagus, a precursor to esophageal cancer.1 Over time, a constant backwash of stomach acid causes the lining of the esophagus to change. Since there are no obvious symptoms, it’s possible to develop precancerous Barrett’s esophagus or esophageal adenocarcinoma without knowing it.1
A variety of factors may contribute to increased risk for disease progression, including:5
While prevalence of Barrett’s esophagus is low in the general population, it’s higher in GERD patients.1
"My father passed away from Esophageal cancer."
HEAR ADAM’S STORY - (02:33)
If you’ve been diagnosed with Barrett’s, odds are, it can’t wait. Talk to your GI about treatment options.
"I didn’t realize what reflux was doing to my esophagus."
HEAR HARRY’S STORY - (03:54)
If you have Barrett’s, watching and waiting isn’t always effective because the disease can progress quickly between endoscopy appointments.8, 9
Talk to your GI about a more proactive approach:
Why Choose Radiofrequency Ablation? - (02:23)
Understand how radiofrequency ablation (RFA) treatments can significantly reduce risk of progression to esophageal cancer.
More information (see more) Less information (see less)
Barrx™ radiofrequency ablation system
The following are transient side effects that may be expected after treatment: chest pain, difficulty swallowing, painful swallowing, throat pain, and/or fever.
Potential complications include mucosal laceration, minor or major bleeding, endoscopic clipping to manage mucosal laceration or bleeding, perforation of the stomach, esophagus or pharynx, surgery to manage perforation, esophageal stricture, endoscopic dilation to manage stricture, pleural effusion, transfusion secondary to major bleeding, cardia arrhythmia, aspiration, infection and death.
If you’ve been living with chronic reflux for years, talk to your doctor.
94% is the calculated relative risk reduction [ (26-1.5)/26] = 25/26 *100. From [25.0% (1.5% for ablation vs 26.5% for control; 95% CI, 14.1%-35.9%; P < .001]
Dam AN, Klapman J. A narrative review of Barrett’s esophagus in 2020, molecular and clinical update. Annals of translational medicine. 2020;8(17):1107.
Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-7.
Labenz J, Chandrasoma PT, Knapp LJ, DeMeester TR. Proposed approach to the challenging management of progressive gastroesophageal reflux disease. World journal of gastrointestinal endoscopy. 2018;10(9):175-183.
Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med 2014;371:836-45.
Muñoz-Largacha JA, Fernando HC, Litle VR. Optimizing the diagnosis and therapy of Barrett’s esophagus. Journal of thoracic disease. 2017;9(Suppl 2):S146-S153.
Schlottmann F, Patti MG. Shaheen NJ. From heartburn to Barrett’s esophagus, and beyond. World journal of surgery. July 2017:
Tofani C, et al. Abstract 69. Presented at: World Congress of Gastroenterology at American College of Gastroenterology Annual Scientific Meeting; Oct. 13–18, 2017; Orlando, FL.
Fleischer DE et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett’s esophagus. Dig Dis Sci 2010; 55(7):1918-31.
Wolf WA, Pasricha S, Cotton C, et al. Incidence of Esophageal Adenocarcinoma and Causes of Mortality after Radiofrequency Ablation of Barrett's esophagus. Gastroenterology. 2015;149:1752-1761.
Phoa KN, van Vilsteren FG, Pouw RE, Weusten BL, Bisschops R, Schoon EJ, et al. Radiofrequency ablation vs. endoscopic surveillance for patients with Barrett’s esophagus and low-grade dysplasia: A randomized clinical trial. JAMA. 2014 Mar 26;311(12): 1209-17.